Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of alpelisib FMIopt versus FMI in healthy volunteers under fed and fasted conditions
NL-OMON46796Active, not recruiting
- Sponsor
- Novartis
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of alpelisib in breast cancer and cancer, sponsored by Novartis. Started May 2018; status: active, not recruiting.
02
Drugs
alpelisib
03
Conditions
breast cancercancer
Beyond the preview
Go deeper on NL-OMON46796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46796.